Assembly Biosciences, Inc. ASMB
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -41.43%
- 1 year
- -36.09%
- Market cap
- 405.58M
- Revenue (ttm)
- 21.48M
- Profit margin
- -212.33%
- EPS (ttm)
- 1.04
- Shares out
- 6.36M
- P/E ratio
- 19.15
- Forward P/E
- -2.12
- YTD return
- -41.43%
- 1-year return
- -36.09%
- Volume
- 170.89K
- Avg volume
- 293.63K
- Open
- 19.71
- Previous close
- 19.51
- Day's range
- 19.50 – 20.32
- 52-week range
- 19.25 – 39.71
- Beta
- 0.59
- Price target
- 35.50 (+78.2%)
- Earnings date
- Mar 27, 2024
2Y +2.99 (+17.61%)
Key statistics
- Enterprise value
- 3.57M
- PEG ratio
- 0.00
- Price / sales
- 4.36
- Price / book
- 1.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 5.50M
- Total cash
- 109.22M
- Total debt
- 1.75M
- Return on equity
- -101.77%
- Short % of float
- 0.38%
- 50-day average
- 16.31
- 200-day average
- 15.02
Analyst view
- Target (low)
- 35.00
- Target (mean)
- 35.50
- Target (high)
- 36.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate -1.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -2.02 | -1.51 | +0.51 | +25.25% |
| Aug 8, 2024 | Jun 1, 2024 | -2.96 | -1.98 | +0.98 | +33.11% |
| May 8, 2024 | Mar 1, 2024 | -2.74 | -1.66 | +1.08 | +39.42% |
| Mar 27, 2024 | Dec 1, 2023 | -2.88 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -2.76 | -3.24 | -0.48 | -17.39% |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | -3.84 | -0.36 | -10.34% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Jun 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Apr 1, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- assemblybio.com
News
UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48 
Assembly Biosciences to Participate in Upcoming Investor Conferences 
Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection 
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus 
Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB) 
Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026 
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 
Best Momentum Stocks to Buy for September 17th 
New Strong Buy Stocks for September 17th 
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Your note
Sign in to keep a note on ASMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJORKQUIST JEANETTE M | Officer | Sale | May 22, 2024 | 3,142 |
| DELANEY WILLIAM E IV | Officer | Stock Award(Grant) | Apr 28, 2024 | 16,109 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 16, 2024 | 1,268,970 |
| MCHUTCHISON JOHN G | Director | Sale | May 22, 2024 | 19,104 |
| OKAZAKI JASON A | Chief Executive Officer | Sale | Oct 2, 2024 | 14,904 |
| SCHORNSTEIN ALEXANDER | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 24, 2024 | 728,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.57% | 354,000 | 5.21M | Sep 29, 2024 |
| Vanguard Group Inc | 3.15% | 200,458 | 2.95M | Sep 29, 2024 |
| Blackrock Inc. | 1.21% | 77,108 | 1.14M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.03% | 65,624 | 965.99K | Sep 29, 2024 |
| Acuitas Investments LLC | 0.98% | 62,315 | 917.28K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.74% | 47,034 | 692.34K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.81% | 114,782 | 1.69M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 66,356 | 976.76K | Sep 29, 2024 |
| Federated Hermes MDT Mid Cap Growth Fund | 0.40% | 25,394 | 373.80K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 23,660 | 348.27K | Oct 30, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.28% | 17,723 | 260.88K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 13,750 | 202.40K | Sep 29, 2024 |